导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.53% | 1598/4773 |
| 近一周 | -3.01% | 3550/5462 |
| 近一月 | -7.56% | 3871/5421 |
| 近一季 | -14.44% | 4154/5209 |
| 近半年 | -4.10% | 2423/4920 |
| 近一年 | 5.22% | 1626/4366 |
| 近两年 | 87.87% | 709/2954 |
| 近三年 | 47.91% | 572/2253 |
| 成立以来 | 125.34% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.50% 912/4961 |
22.87% 1114/5312 |
- - |
- - |
| 2025 | 43.57% 661/4813 |
5.03% 841/3635 |
5.90% 525/4076 |
30.37% 1180/4524 |
-1.00% 2771/4813 |
| 2024 | 3.57% 1916/3463 |
-7.76% 2185/2808 |
-2.67% 1224/3014 |
15.47% 1708/3129 |
-0.09% 1318/3463 |
| 2023 | -9.33% 1150/2656 |
5.42% 786/2280 |
-0.78% 417/2385 |
-9.96% 1916/2515 |
-3.73% 773/2655 |
| 2022 | -27.92% 1516/2207 |
-18.87% 1406/1919 |
6.32% 724/2016 |
-14.36% 1079/2113 |
-2.43% 1806/2208 |
| 2021 | 21.27% 163/1822 |
-5.46% 926/1255 |
25.26% 92/1330 |
-3.25% 623/1466 |
5.85% 261/1822 |
| 2020 | 58.97% 130/1250 |
2.44% 135/1028 |
29.99% 66/1067 |
8.30% 723/1164 |
10.22% 608/1184 |
| 2019 | 44.08% 180/1092 |
29.30% 280/754 |
-6.62% 515/804 |
9.49% 55/850 |
8.98% 266/918 |
| 2018 | - - |
- - |
- - |
- - |
-9.32% 141/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 海富通创业板增强C VS. 长安沪深300非周期A(740101) |